Prof. Amal employs advanced omics technologies and computational biology, along with techniques from biochemistry, pharmacology, and behavioral science, to explore the integration of signaling pathways at molecular, cellular, and systemic levels that regulate cellular functions. His laboratory utilizes proteomics to assess protein expression and their post-translational modifications (PTMs), offering crucial insights into the cellular state. Combined, this interdisciplinary approach is used to identify potential drug targets and biomarkers for a variety of conditions, including aging and related diseases such as Alzheimer's disease (AD).

Prof. Arzy has applied advanced computational tools to develop new methods for very early identification of patients at risk for Alzheimer's disease. In addition, he uses computational methods to analyze impairments in the orientation abilities of Alzheimer's patients, holding the promise of assisting elderly Alzheimer's patients with orientation and thus safer mobility.

Prof. Ben-Neriah is a world-leading cancer researcher. He has developed a new biological drug for acute myeloid leukemia (AML) which is currently in clinical trials. Prof. Ben-Neriah is studying how mutations accumulate in the body, and, specifically, in blood cells, during age, and how this affects aging and cancer development.

Prof. Bergman studies the basal ganglia and Parkinson's disease. He is best known for the development of the groundbreaking surgical treatment for Parkinson's patients – deep brain stimulation (DBS). More than 30,000 Parkinson's patients have benefited from Prof. Bergman's innovative therapy and DBS is now standard care therapy for most Parkinson's patients.

Prof. Cohen focuses his research on the aberrant protein aggregation that is a common feature of human neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Why these maladies onset late in life and whether the aging process plays active roles in allowing their manifestation are key questions that are addressed in his lab. His aim is to harnessing the mechanisms that prevent the onset of neurodegenerative diseases early in life to protect the elderly from these devastating maladies.

Prof. Elkouby has developed a multidisciplinary approach to studying the developing ovary, pioneering the use of deep-learning methods and live microscopy to track egg production. His research has led to significant breakthroughs in our understanding of human reproduction. Notably, his lab investigates the reproductive aging in human females, caused by the cessation of egg production over time. By studying the zebrafish ovary—where egg production is continuous and similar to humans—his team aims to uncover the fundamental mechanisms of ovarian reproductive regeneration and identify the key factors absent in humans. Prof. Elkouby has received prestigious awards, including the ZCAI Prize for Discovery in Medical Research, an ERC Consolidator Grant, and the EMBO Young Investigator Award.

Dr. Gross studies the delicate balance of oxygen regulation. Oxygen metabolism creates reactive oxygen species that may underlie the development of many pathological conditions including atherosclerosis (hardening of the arteries), Alzheimer's and Parkinson's disease, and many age-associated diseases. He uses a worm model to explore oxygen metabolism, using imaging techniques, biochemistry, genetics, and behavioral experiments.

Dr. Harel's goal is to understand how organisms age. To address this challenge, he recently developed a comprehensive genetic platform for rapid exploration of aging and disease in the shortest-lived vertebrate, the African turquoise killifish. Using this emerging model, he is trying to answer fundamental questions in biology. Specifically, his lab focuses on identifying novel approaches for extending health span, and better understanding why aging is such a strong driver of disease.

Prof. Keshet has pioneered the molecular understanding of blood vessel formation, known as angiogenesis, as well as its connection to cancer and cardiovascular diseases, which has led to new treatment modalities for cancer and blindness-causing macular degeneration.  Among his many recognitions and awards are the EMET Prize, the Rothschild Prize, the TEVA Prize, and the North American Vascular Biology Organization (NAVBO) Prize.

Dr. Mansour is working on using stem cell-based technology to understand and develop therapeutics for neurodegenerative diseases of aging such as Alzheimer's and Parkinson's and has engineered brain-like tissue (mini-brain) in the lab, allowing him to study neurodegenerative diseases processes and potential therapeutic strategies outside of the human body.

Dr. Nitzan's research is focused on the representation, inference and design of multicellular systems. She develops models and computational frameworks to better understand how cells encode multiple layers of spatial and temporal information, and how to efficiently decode that information from data such as single-cell RNA-sequencing and spatial transcriptomics data. Dr. Nitzan aims to uncover organization principles underlying collective cellular behavior, such as information processing, computation, division of labor, and self-organization of multicellular structures, as well as the disruption of these processes in disease. Projects related to aging include characterizing changes in cellular order, diversity, and function during aging, and identifying maximally informative gene expression signatures for age-related diseases like Alzheimer's disease.

Prof. Sharon is interested in the biochemistry, molecular and cell biology of neuronal degeneration during aging of the mammalian brain, particularly in Parkinson's disease and related neurodegenerations, collectively called synucleinopathies. The laboratory originally developed methods for the detection and analysis of α-Synuclein protein, which is the pathogenic hallmark of the neuropathology of age-related synucleinopathies. She investigates the normal physiological function of α-Synuclein and the mechanism by which α-Synuclein mutations produce neurodegenerations.

Dr. Tzur delves into the mechanisms governing germline aging. Employing both simple model organisms and human samples, his research looks at how the development of oocytes and sperm alters over time. His team is dedicated to pinpointing the genetic and biochemical pathways underlying these changes and exploring strategies to control them. Ultimately, the overarching aim is to pioneer techniques facilitating fertility procedures in individuals of advanced age.

Prof. Weiner is interested in the molecular mechanisms of protein modifications by ubiquitin-like proteins (UBLs). The connection between protein modifications by UBLs and aging is highly appreciated over the last few years and the work in the lab aims to expose new targets for anti-aging drug development.